ENGAGE run · e51de0a31ae1

```json [ { "post_index": 1, "cluster_ids": [5, 10], "claim": "CMS Medicare market pilot expansion creates reimbursement risk for GLP-1 drug access", "argument_type": "empirical_claim", "stance": "neutral_analysis", "hyde_excerpt": "The July 2026 Medicare market expansion for GLP-1 therapies presents a dual-edged reimbursement scenario. While the 1.5-year pilot could unlo

Looking at each post carefully against the article catalog, applying strict match quality standards: **Post [0]** - Insurance denial/hospital complaint story. No healthcare systems analysis. Excluded by [healthcare_fraud_scandal_without_systems_analysis]. **Post [1]** - Anti-vaccine content about Gardasil. Clinical research observation without systems context. No match. **Post [2]** - NYT bests

The reimbursement risk framing is right but it undersells where the actual friction lives. The problem for Lilly and Novo isn't access to the market, they negotiated BALANCE terms, got the safe harbor structure, had net price anchors in Appendix C. The problem is there's no Part D channel to deploy those terms into for 2027. The 80 percent NAMBA-weighted threshold in the March RFA required nearly

The decertification news is genuinely significant, but the "declared dead too quickly" framing conflates two separate problems that have very different policy implications. Concerns about brain death determination protocols are a clinical and consent question. OPO underperformance is a procurement process question. Mixing them in the same reform conversation gives OPOs a convenient deflection: if

The question this raises that I can't stop thinking about: are those sub-$300K physicians in the wrong specialties, or are they actually in the right ones and the system is just failing them? My own work on actuarial value creation suggests it's the latter. Pediatricians, by my calculations, are underpaid by 72% relative to their measurable contributions, generating $720,000 in annual system savi

Radiology is already living this split. Aidoc and Viz.ai are running triage and flagging incidentals at volume, the radiologist reads the hard cases and signs off on the workflow, throughput goes up, billing stays intact. The demand curve per-radiologist shifts, you are correct about that, but compensation at starting offers above $600K tells you the market has not priced in replacement. The more

Tracked this exact bifurcation in a piece on clinical AI investment signals, and the UCLA ambient scribe study is a useful anchor point here. That trial randomized 238 physicians across 72,000 encounters, used the Stanford Professional Fulfillment Index and NASA Task Load Index as outcome measures, not homegrown surveys, and got published in NEJM AI. The 41-second documentation reduction per note

The 50-day wait is real, but the referral bottleneck is doing more work in that number than the neurologist shortage itself. A chunk of those queued patients don't need a face-to-face neurology visit. They need a PCP who had enough clinical backup to manage the case in-house, or at minimum triage it more precisely before sending it forward. When I dug into referral patterns, the finding that keep

Worked with a self-funded school district last year that was paying $4,000 for MRIs their employees could have accessed at cash prices closer to Medicare's $450 reimbursement rate. The spread is real and it's that wide. The loophole you're describing is the core mechanism. Providers can post cash prices under the CMS transparency rule but still route insured patients through contracted rates, whi

The hard part isn't the transformer architecture, it's what came before it. Deeply phenotyped cohorts take years to assemble (the Alzheimer's multimodal datasets I looked at were stuck at dozens-to-thousands of patients precisely because harmonization was the bottleneck, not the science). Congrats on the preprint, curious how you're handling fusion across modalities at inference time. https://www

Hypertension alone costs $131 billion annually in the U.S., and that number is built almost entirely on late-stage burden, meaning the bill gets written long before anyone sees a doctor. The real pressure point in what you're describing is what happens when that undiagnosed BP sits under a primary diagnosis for years. In my own work at https://www.onhealthcare.tech/p/breaking-down-the-most-expens

The pharmacogenomic angle is genuinely underexplored here, but the downstream operational question it raises might matter more to payers than the science itself. If genetic variation predicts differential response, that creates pressure to build a pre-authorization layer that accounts for likely efficacy, not just clinical indication. Which is a different kind of infrastructure problem than what m

```json [] ```

[]

```json [ {"post_index": 0, "prediction": "reject", "confidence": 95, "reason": "completely off-topic entertainment content, no healthcare relevance"}, {"post_index": 1, "prediction": "reject", "confidence": 85, "reason": "personal offer about DNA sequencing without healthcare systems context or

```json [ { "category": "ai_safety_vulnerability_incident_tangential", "summary": "Posts about AI safety incidents, security vulnerabilities, or model jailbreaks that lack healthcare systems context", "exclusion_rule": "Exclude posts about AI model vulnerabilities, security breaches, o